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Lipophilic yeasts of the genus Malassezia are important skin commensals and
opportunistic skin pathogens in a variety of animals. The speciesM. pachydermatis was
first isolated from the skin of a captive Indian rhinoceros with an exfoliative dermatitis
in 1925, recognized as an important otic pathogen of dogs in the 1950’s, and finally
accepted, after several years of controversy, as a common cause of canine dermatitis
in the 1990’s. Since then, there has been considerable research into the biology of
Malassezia yeasts and their interaction with their animal hosts. In dogs and cats,
M. pachydermatis is associated with ceruminous otitis externa and a “seborrhoeic”
dermatitis, wherein pruritic, erythematous skin lesions, often with brown/black greasy,
malodourous material matting hairs, preferentially develop in intertriginous areas. Skin
disease is favored by folds, underlying hypersensitivity disorders, endocrinopathies,
defects of cornification, and in cats, various visceral paraneoplastic syndromes.
Diagnosis is based on detecting the yeast in compatible skin lesions, usually by cytology,
and observing a clinical and mycological response to therapy. Treatment normally
comprises topical or systemic azole therapy, often with miconazole—chlorhexidine
shampoos or oral itraconazole or ketoconazole. Management of concurrent diseases is
important to minimize relapses. Historically, wild-typeMalassezia isolates from dogs and
cats were typically susceptible to azoles, with the exception of fluconazole, but emerging
azole resistance in field strains has recently been associated with either mutations
or quadruplication of the ERG11 gene. These observations have prompted increased
interest in alternative topical antifungal drugs, such as chlorhexidine, and various essential
oils. Further clinical trials are awaited with interest.
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INTRODUCTION
The genus Malassezia is comprised of a group of lipophilic yeasts that have evolved as
skin commensals and opportunistic cutaneous pathogens in a variety of mammals and birds
(Guého-Kellerman et al., 2010). The transition from commensal to pathogen is frequent in dogs in
particular, and in cats to a lesser extent, such that cases ofMalassezia otitis externa andMalassezia
dermatitis are commonly presented to veterinarians in small animal practice (Moraru et al., 2019).
For example, the prevalence of otitis externa amongst dogs presenting to primary care practices
is around 10% (O’neill et al., 2014), and up to 70% of such cases may be associated with M.
pachydermatis (Forster et al., 2018). These cases are seldom straightforward to manage, because
clinical disease often reflects yeast proliferation due to a disturbance in the normal homeostatic
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balance of host immunity, on the one hand, and yeast virulence,
on the other (Ashbee and Bond, 2010). Thus, successful case
management is often dependent upon both treating yeast (and
any concurrent bacterial) overgrowth with topical or systemic
antimicrobial treatments, as well as identifying and correcting
where possible, predisposing factors. Commonly identified
factors include concurrent allergic or endocrine skin disease,
defects in cornification, or anatomical defects such as skin
folds or stenosed ear canals (Bond et al., 2010). By contrast,
there are only sporadic reports of Malassezia associated with
skin disease in large animal species. For example, Malassezia
overgrowth in the intermammary region and preputial fossa has
been implicated in tail-head pruritus and localized dermatitis in
horses (White et al., 2006). Goats may present with Malassezia-
associated seborrheic dermatitis (Pin, 2004; Eguchi-Coe et al.,
2011).Malassezia otitis has been reported in fennec foxes (Guillot
et al., 1994), ferrets (Dinsdale and Rest, 1995), pigs (Pinter et al.,
2002), and camels (Kuttin and Glas, 1985).
Recently, the World Association of Veterinary Dermatology
commissioned the development of clinical consensus guidelines
for the diagnosis and treatment of Malassezia dermatitis in dogs
and cats (Bond et al., 2020). A panel of specialists/diplomates
in veterinary dermatology and mycology prepared a detailed
literature review of publications up to mid 2018, and made
recommendations on selected topics. The draft document was
presented at international veterinary meetings and uploaded on
the WAVD website for comment for a period of 6 months.
The final version comprised a systematic review of published
therapeutic studies, and current information on the ecology,
pathophysiology, diagnosis, and prevention of skin diseases
associated withMalassezia yeasts in dogs and cats.
In view of the free access availability of this recent very detailed
and wide-ranging review (Bond et al., 2020), the present article
aims to provide the reader with a general background summary
of current understanding of the roles of Malassezia yeasts in
animal skin disease, with emphasis on recent publications from
mid 2018 to end of 2019 that expand upon previous knowledge.
THE GENUS MALASSEZIA: A GROWING
NUMBER OF SPECIES IN A GROWING
NUMBER OF ANIMAL HOSTS
Originally thought as a single species, Malassezia yeasts are
now known to form a unique cluster consisting of 18 species
living almost exclusively on the skin and mucosal sites of warm-
blooded vertebrates (Lorch et al., 2018; Theelen et al., 2018)
(Table 1). During the last decade, the analysis of the genome of
Malassezia yeasts suggested that their ancestors were plant or
soil fungal residents which progressively managed to survive and
develop in the cutaneous ecosystem (Xu et al., 2007). The genus
Malassezia (Baillon) was created in 1889 for a single species,
M. furfur, detected in cutaneous lesions in humans (Baillon,
1889). Weidman was the first scientist to detectMalassezia yeasts
from the skin of an animal, an Indian rhinoceros (Rhinoceros
unicornis) with a generalized exfoliative dermatitis (Weidman,
1925). In contrast to M. furfur these yeasts cultivated readily on
TABLE 1 | Malassezia species and main mammalian hosts.
Malassezia
species
Synonyms Presence on
healthy skin
Presence in lesions
M. furfur Pityrosporum ovale In humans
Sometimes
in animals
In humans (PV, FG)
M. pachydermatis P. pachydermatis,
P. canis
In dogs, cats,
many others
(mostly canids)
Sometimes in
humans (dog
contact)
In dogs, cats, others
(SD, OT)
Sometimes in
humans (FG)
M. sympodialis M. furfur serovar A In humans and
animals
In humans (AD, SD)
Sometimes in cats (OT)
M. globosa P. orbiculare
M. furfur serovar B
In humans and
animals
In humans (PV, SD, AD)
Sometimes in cats (OT)
M. obtusa In humans In humans
M. slooffiae In pigs, cats
(claws)
In humans
In humans
M. restricta M. furfur serovar C In humans In humans (SD)
M. dermatis In humans In humans (AD)
M. japonica In humans In humans (AD, SD)
M. nana In cats, horses In cats, cattle (OT)
M. yamatoensis In humans In humans (SD)
M. caprae In goats
M. equina M. equi In horses In horses
M. cuniculi In rabbits
M. arunalokei In humans In humans
M. brasiliensis In parrots –
M. psittaci In parrots –
M. vespertilionis In hibernating bats –
–, not reported; PV, pityriasis versicolor; FG, fungaemia; AD, atopic dermatitis; SD,
seborrheoic dermatitis; OT, otitis.
routine media without lipid supplementation. Malassezia yeasts
were further detected from different warm-blooded vertebrates
and several specific names were proposed according to the latin
names of the animals on which the yeasts were initially isolated:
M. pachydermatis (from a rhinoceros within Pachydermata,
an obsolete nineteenth-century taxonomic order of mammals)
(Weidman, 1925), M. caprae from goats (Cabanes et al., 2007),
M. equina from horses (Cabanes et al., 2007), M. cuniculi
from rabbits (Cabanes et al., 2011), M. pstittaci from parrots
(Cabanes et al., 2016), and very recently M. vespertilionis from
bats (Lorch et al., 2018). Some Malassezia yeasts (especially
M. pachydermatis) appear to have a broad host range, while
others are more host-specific with a close adaptation to the
cutaneous ecosystem of a single animal species or a group
of phylogenetically related animals (Table 1). The number of
currently described Malassezia species (n = 18) is likely limited
due to a sampling bias toward humans and domestic animals. We
can imagine that the number of Malassezia species will increase
when the skin microbiota of a broader range of wild animals
is investigated.
Very recently, Lorch et al. were able to isolate a newMalassezia
species from the skin of nine species of bats in the subfamily
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Myotinae in eastern and western United States (Lorch et al.,
2018). Physiological features and molecular characterization at
seven additional loci clearly demonstrated that all of the bat
Malassezia isolates represented a single and new species which
was designated asM. vespertilionis. Among other characteristics,
the new species is able to grow over a broad range of temperatures
(7–40◦C), with optimal growth occurring at 24◦C. The authors
suggested that the wide thermal growth range may be an
adaptation to survival on bat skin during both hibernation and
active seasons (Lorch et al., 2018).
RECENT RE-ASSESSMENTS OF
LIPID-DEPENDENCE IN MALASSEZIA
PACHYDERMATIS
Malassezia species are lipid dependent due to an inability
to synthesize long-chained (C14 or C16) fatty acids de novo
(Shifrine and Marr, 1963). There are some differences in lipid
dependence among the species and this variability has been
used for the development of specific tests for their identification
(Guillot et al., 1996). HistoricallyM. pachydermatis was regarded
as being “lipophilic but not lipid-dependent” because it was the
only member of the genus to grow on Sabouraud’s dextrose
agar (Guillot and Bond, 1999). Recently, genome sequencing
has confirmed that M. pachydermatis lacks a fatty acid synthase
gene like the other members of the genus (Wu et al., 2015),
but is uniquely able to utilize lipid fractions within the peptone
component of Sabouraud’s dextrose agar for growth (Puig et al.,
2017). These observations explain its failure to grow on lipid-
free defined media and thus M. pachydermatis should now also
be regarded as being “lipid-dependent” (Puig et al., 2017).
ECOLOGY OF MALASSEZIA YEASTS IN
DOGS AND CATS: COMPLEMENTARY AND
CONFLICTING RESULTS FROM
TRADITIONALLY CULTURE-BASED
STUDIES AND MORE RECENT
MOLECULAR INVESTIGATIONS
To better understand the ecology ofMalassezia yeasts on healthy
skin and in cases of cutaneous lesions, culture-based studies
have been carried out both in humans (Gaitanis et al., 2012)
and in animals, especially in dogs (reviewed by Bond et al.,
2020). Results vary between studies because of the use of
different sampling procedures, culture media, and identification
techniques. However, culture-based studies clearly demonstrate
that M. pachydermatis is the predominant cutaneous yeast in
both healthy dogs and dogs with Malassezia dermatitis or otitis
(Gustafson, 1955; Dufait, 1985; Hajsig et al., 1985; Bond and
Lloyd, 1997).M. pachydermatis is also most important in cats but
in this host otherMalassezia species are more frequently detected
(Hajsig et al., 1990; Hirai et al., 2004; Åhman et al., 2007a; Åhman
and Bergstrom, 2009; Volk et al., 2010). Several investigators
explored Malassezia colonization in various anatomical regions
of different breeds of adult healthy dogs (reviewed by Bond et al.,
2020). The general conclusion from these studies is that the peri-
oral region and interdigital skin is frequently colonized (up to
80%) by M. pachydermatis in healthy dogs of various breeds,
whereas the yeast is less-often (<25%) detected on the skin of
the axilla, groin and dorsum. The skin of cats may be colonized
by several Malassezia species. Whilst M. pachydermatis remains
most prevalent, as in dogs, the lipid-dependent species isolated
from cats includeM. sympodialis,M. globosa,M. furfur,M. nana,
and M. slooffiae (reviewed by Bond et al., 2020). M. nana is
the most common lipid-dependent species in cats, particularly
in the ear canal, and a particular M. nana genotype seem to
predominate in this animal host (De Bellis et al., 2009; Castella
et al., 2011). M. slooffiae is primarily but not exclusively isolated
from claw folds in cats (Åhman et al., 2007a).
Recently, methods based on next generation sequencing
(NGS) have allowed a better characterization of the complex
microbial communities occurring on animal skin and made it
possible to detect Malassezia species that would otherwise be
missed using culture-based methods (Meason-Smith et al., 2017,
2019; Korbelik et al., 2018; Older et al., 2019).Meason-Smith et al.
reported that the cutaneous mycobiota in dogs was influenced by
various factors including environmental exposure, cohabitation
with other pets and skin health status (Meason-Smith et al.,
2015). Surprising,Malassezia yeasts were not the most abundant
fungal organisms on healthy canine skin. Furthermore, these
authors were unable to detect any significant differences in the
relative abundance of Malassezia yeasts between healthy and
allergic dogs. The discrepancy between NGS results and culture-
dependent studies demonstrating increased populations of M.
pachydermatis in allergic dogs (Bond et al., 1994; White et al.,
1998) may be related to differences in methodology. Another
explanation would be that dysbiosis is present at Malassezia
species level (rather that at M. pachydermatis abundance) in
allergic dogs. This hypothesis was very recently investigated by
Meason-Smith et al. who collected skin samples from healthy,
naturally affected allergic, and experimentally sensitized atopic
dogs (Meason-Smith et al., 2019). Using NGS (at species level
classification) and Malassezia species-specific quantitative real-
time PCR (qPCR), they demonstrated that M. globosa was
significantly more abundant on healthy canine skin (by both
methods), M. restricta was significantly more abundant on
healthy skin (by NGS), and M. pachydermatis was significantly
more abundant on naturally-affected allergic skin (by NGS) and
on allergen-induced atopic skin lesions (by qPCR).
The NGS method was also recently applied to better
understand the mycobiota in the external ear canal of dogs
(Korbelik et al., 2018). Samples were collected from six dogs with
otitis externa and five clinically normal dogs. In cases of otitis
externa, the mycobiota was largely dominated by Malassezia
yeasts. Fungal species diversity, richness and evenness were
all significantly reduced in samples from otitis externa when
compared to healthy ears.
In cats, metagenomic analyses suggested that the skin is
inhabited by bacterial communities that are distinct to each
body site (Older et al., 2017) whereas fungal communities seem
more unique to the individual level (Meason-Smith et al., 2017).
When samples from healthy and allergic cats were collected, the
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most abundant fungal sequences were identified as filamentous
contaminants from the environment and not Malassezia yeasts,
which were identified in 30 and 21% of healthy and allergic
cat samples, but rarely accounted for more than 1% of the
relative fungal abundance (Meason-Smith et al., 2017). The
objectives of the recent study from Older et al. were to evaluate
how genotype and environment can influence the bacterial and
fungal microbiota of feline skin (Older et al., 2019). Using
NGS and Malassezia qPCR, they demonstrated that M. restricta
and M. globosa were the most prevalent Malassezia species.
Sequences corresponding to M. slooffiae, M. furfur, M. nana,
M. pachydermatis, M. dermatis, M. sympodialis, M. japonica,
M. obtusa, and M. yamatoensis were also detected. Malassezia
abundance was significantly different between cat breeds with
Devon Rex cats having the highest abundance. No significant
difference in abundance of any Malassezia species were found
between the different cat breeds or when comparing indoor and
outdoor animals.
Taken together, these studies demonstrate significant disparity
between cultural andmolecular studies in defining theMalassezia
species component of the skin mycobiota in dogs and cats.
Importantly in dogs, cultural methods seldom demonstrate
Malassezia species other than M. pachydermatis in both health
and disease, even when culture media reputed to support the
growth of the more lipid-dependent species such as modified
Dixon’s agar are utilized (reviewed by Bond et al., 2020). By
contrast, molecular techniques indicate the frequent presence of
M. globosa andM. restricta, species that are seldom identified by
culture (Meason-Smith et al., 2019), despite years of searching
by the present and other authors (Guillot and Bond, 1999).
Furthermore, the distinctive morphology of M. globosa (Guého-
Kellerman et al., 2010) is not systematically observed in clinical
cytological specimens from dogs with dermatitis (Bond, R.,
personal observations). When presented with a clinical case,
it may not be strictly necessary for the attending veterinarian
to know the species identity of the Malassezia causing the
disease, provided species variation in drug susceptibility is
limited (Tragiannidis et al., 2010). Further developments in both
diagnostic and antifungal drug susceptibility testing are urgently
required to address these aspects.
PATHOGENESIS OF MALASSEZIA
DERMATITIS IN DOGS AND CATS:
BACKGROUND AND RECENT ADVANCES
There have been significant and recent advances in
understanding of the mechanisms of interaction between
Malassezia yeasts and dogs and cats (reviewed by Bond
et al., 2020). The outcome of Malassezia growth on the skin
(commensal existence or inflammation and disease) is dependent
upon the metabolic activities of the yeasts (expression of cell
wall and secreted virulence attributes) and the host’s innate and
adaptive immune defensive responses. Interactions with other
skin commensals (especially staphylococci) may also play a role
in determining the outcome of colonization in animals, although
this area is largely unexplored (Ianiri et al., 2018), especially
in dogs and cats. All these processes should ideally result in a
delicately balanced homeostatic relationship. The presence of
Malassezia yeasts within the stratum corneum exposes the host
to an array of chemicals, immunogens and allergens, comprising
fungal cell wall-associated carbohydrates, proteins and lipids;
secreted enzymes that generate both substrates for nutrition, and
an array of irritant metabolic by-products (reviewed by Ashbee
and Bond, 2010; Sparber and Leibundgut-Landmann, 2017).
In a recent investigation, Czyz˙ewska et al. compared the
protein profiles of M. pachydermatis isolates from 30 dogs
with clinical signs of otitis externa and 34 clinically normal
dogs (Czyz˙ewska et al., 2019). The most significant finding was
the presence of nicotinamide adenine dinucleotide phosphate
(NADP)-dependent mannitol dehydrogenase and ketol-acid
reducto isomerase (an enzyme involved in the biosynthesis of
branched-chain amino acids) among M. pachydermatis isolates
obtained from dogs with otitis externa. It is not clear whether
these enzymes confer an advantage to the yeast or act as virulence
factors (Czyz˙ewska et al., 2019).
Malassezia cell wall carbohydrates are recognized as IgE
binding epitopes in humans with atopic dermatitis but recent
work highlighted their importance in fungal cell recognition
by host phagocytic cells. C-type lectins are proteins that bind
carbohydrates in a calcium-dependent manner via highly-
conserved carbohydrate-recognition domains (Tada et al., 2006).
Mincle, a C-type lectin expressed by activated phagocytes that
binds glucosyl and mannosyl-glycolipids fromM. pachydermatis
and M. sympodialis, selectively recognizes Malassezia yeasts
but not other fungi (Yamasaki et al., 2009). Recently, van
der Peet et al. reported the total synthesis of a complex β-
1,2-mannosyloxymannitol glycolipid from M. pachydermatis,
which was a potent agonist of human Mincle signaling; these
observations may have relevance in the further understanding
of antifungal immunity (Van Der Peet et al., 2019). Whilst it is
intuitive that similar mechanisms may occur in dogs and cats,
species-specific studies are required to verify this.
A recent study suggested that M. pachydermatis is able to
activate the aryl hydrocarbon receptor (AhR), a nuclear receptor
and transcriptional regulator with pleiotropic effects that
include down-regulation of immune stimulation, modification
of melanogenesis and epidermal cell function, and inhibition
of antagonistic microbes (Buommino et al., 2018). Since indole
production was not detected in a study of 80 M. pachydermatis
strains from canine otitis externa, AhR activation by M.
pachydermatismight be associated with the release of compounds
other than indolic metabolites (Kiss et al., 1996).
Experimental models have been used to better understand
the pathogenesis of Malassezia dermatitis. Cutaneous responses
to the application of viable and killed “lipid-dependent”
Malassezia in laboratory animals (guinea pigs, mice, rabbits)
generally comprised focal areas of scaling that most often
resolve without treatment upon discontinuation of inoculation
(Drouhet et al., 1980; Rosenberg et al., 1980; Faergemann
and Fredriksson, 1981; Van Cutsem et al., 1990). Similarly, in
laboratory beagle dogs, application of M. pachydermatis was
associated histologically with epidermal hyperplasia, occasionally
with parakeratosis, superficial perivascular dermal inflammation
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with primarily neutrophils and lymphocytes, and sometimes
mast cells (but not eosinophils); features were more severe
at sites that were occluded (Bond et al., 2004). Histological
changes markedly reduced within 7 days of withdrawal of yeast
challenge. Inoculation of suspensions of M. pachydermatis into
the middle ear and dermis of immunosuppressed mice led to
transient infection that resolved within 21 days (Schlemmer
et al., 2018). Recently, Merkel et al. developed a minihost
(invertebrate) experimental model wherein the pathogenicity of
M. pachydermatis was evaluated in wild-type (WT) and Toll-
deficient Drosophila melanogaster. WT flies were resistant to
the infection, whereas Toll-deficient flies showed inoculum-
dependent mortality rates. Experimental models may prove
valuable in the further elucidation of both yeast virulence and
host immune factors that are important in disease processes in
various species.
The presence ofMalassezia yeasts on the skin, both in normal
and excessive numbers, is known to activate the skin immune
system in dogs and cats. Malassezia antigens can stimulate
innate, antibody and cell mediated immune responses, as well
as triggering hypersensitivity reactions (Bond et al., 2010). In
animals in which an overgrowth of organisms has occurred, or
in individuals that are predisposed to allergic sensitization, the
ensuing inflammatory response can lead to clinical signs such
as dermatitis and pruritus. Elevated IgE levels to Malassezia
yeasts or Staphylococcus bacteria in human atopic dermatitis are
related to the skin severity index. To assess whether a similar
association occurs in dogs, Khantavee et al. investigated levels
of allergen-specific IgE, IgG1, and IgG2 directed against M.
pachydermatis and S. pseudintermedius, with total IgG levels,
and correlated them with lesion severity in dogs with atopic
dermatitis (Khantavee et al., 2019). They reported that specific
IgE and total IgG against yeasts and bacteria were significantly
increased in atopic dogs of all ages. However, no significant
relationships were found between the clinical score and any
specific immunoglobulin levels for both microbe types.
PREDISPOSING FACTORS FOR SKIN
DISEASE IN DOGS AND CATS
Ideally commensal Malassezia yeasts behave as “good citizens”
and occupy their ecological niche within the “transitional mantel
zone” of the epidermal stratum corneum and follicular
infundibulae, influenced by host skin and the external
environment (Theelen et al., 2018). Normally, continuous
interactions with the host immune system will maintain low
numbers of the yeast without generating a clinically-appreciable
inflammatory response (Bond et al., 2020). It is well-recognized
that Malassezia dermatitis in dogs and cats is most often
associated with concurrent diseases that are likely associated with
altered skin immune function and/or changes in the chemical
and micro-climatic conditions at the skin surface (Bond et al.,
2020). Thus in dogs, hypersensitivity disorders (especially canine
atopic dermatitis), defects of cornification and endocrinopathies
are frequently recognized as underlying factors that must be
corrected or managed as part of the therapeutic programme
(Bond et al., 1996b). Skin folds commonly represent an important
local factor in favoring overgrowth byMalassezia and or bacteria;
this likely reflects local climatic differences involving factors
such as reduced air movement, increased skin temperature and
humidity, retained secretions, and surface frictional trauma
(Jenkinson, 1992). Although not specifically studied in the dog,
it is also generally recognized that Malassezia dermatitis is more
common in tropical climates, and during warm, humid months
in more temperate latitudes, reflecting external environmental
effects on the skin microbiota (Theelen et al., 2018). This factor
is well-documented in human medicine, with warm tropical
climates favoring high positive culture rates and greater species
diversity (Gaitanis et al., 2012; Leong et al., 2019).
Predisposition to Malassezia dermatitis in cats parallels the
canine situation in many ways with one important exception.
Whilst skin folds and allergic diseases are also commonly
identified as factors (Ordeix et al., 2007), feline Malassezia
dermatitis in older cats is occasionally associated with visceral
neoplasia, most commonly feline (pancreatic) paraneoplastic
alopecia and thymoma-associated exfoliative dermatitis (Forster-
Van Hijfte et al., 1997; Mauldin et al., 2002).
Dog breeds identified to be at increased risk of Malassezia
dermatitis include West Highland white terriers (WHWT),
English setters, shih tzus, basset hounds, American cocker
spaniels, boxers, dachshunds, poodles, and Australian silky
terriers (Mason, 1992; Plant et al., 1992; Bond et al., 1996b;
Mauldin et al., 1997). Devon rex and Sphynx cats, but not
Cornish rex cats, are prone to high carriage rates of Malassezia
yeasts (defined by culture) and a generalized seborrhoeic
dermatitis that responds to oral itraconazole (Åhman et al.,
2007a,b; Åhman and Bergstrom, 2009; Volk et al., 2010). These
breed predilections in dogs and cats are likely analogous to
the observed effects of ethnicity on Malassezia populations on
human skin (Leong et al., 2019).
A recent study that utilized next generation sequencing (NGS)
to study fungal populations on skin and mucosae in various cat
breeds also reported that Devon rex cats had a high abundance
of Malassezia species (Older et al., 2019). Interestingly, species-
level analyses of the sequences identified M. globosa and M.
restricta as the most abundant Malassezia species in the subject
cats (Older et al., 2019). In contrast, previous cultural studies
typically identifyM. pachydermatis as the most abundant species
in cats, even when media (for example, modified Dixon’s agar)
and temperatures (32–34◦C) considered appropriate for the
cultivation of the more demanding species are adopted (Bond
et al., 1996a, 1997, 2008; Volk et al., 2010). Further investigation
of these discordant results is warranted.
CLINICAL PRESENTATIONS IN DOGS AND
CATS
Affected skin is usually erythematous, often with greasy
brown-black material matting the lower portion of hairs;
intertriginous zones are frequently involved (Bond et al.,
2010). Pruritus, whilst ranging from minimal to severe, is
normally a dominant feature. Concurrent hyperpigmentation,
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lichenification, malodour, traumatic alopecia, and otitis externa
is common. In otitis externa, the discharge from the ear canal
is commonly ceruminous and rarely purulent, and inflammation
commonly extends onto the pinnae. Cases of Malassezia
paronychia present with claw fold erythema and swelling, waxy
or crusty brown exudate, red-brown claw staining, and may co-
exist with a wider pododermatitis of haired skin. An occasional
presentation of frenzied facial pruritus in dogs with varying,
sometimes subtle, erythema of chin / perioral skin, may be
misdiagnosed as neurological disease (Mason, 1992, 1993).
The signs ofMalassezia dermatitis may mimic, or complicate,
those of canine atopic dermatitis. Features of concurrent diseases
may be evident initially although they are commonly best
appreciated once secondary Malassezia infection is removed.
Malassezia dermatitis might feature in cats that present with a
phenotype of allergic skin disease, idiopathic facial dermatitis
(Persian/Himalayan), feline acne, and serious internal medical
disorders such as feline paraneoplastic alopecia and thymoma-
associated exfoliative dermatitis (Bond et al., 2010). Client
expectation should be managed accordingly; residual skin disease
commonly remains despite successful antifungal therapy.
DIAGNOSTIC APPROACH IN THE
VETERINARY CLINIC
Following the original elegant description of tape-stripping in
human dermatology (Keddie et al., 1961), this method has
gained wide acceptance in veterinary clinical practice as a rapid
and versatile method for recovering stratum corneum cells and
their attendant adherent microbes (Maynard et al., 2011). Light
microscopical examination (40–50 or 100x oil objectives) of tape-
strips, or dry scrapes, stained with modifiedWright Giemsa stain
(“Diff-Quik” or generic equivalents) is rapid and convenient for
assessment of the presence and numbers of Malassezia yeasts
(Moraru et al., 2019). Factors such as important variations in
anatomical site, breed, sampling method and host immune status
commonly thwart the interpretation of the clinical significance of
an observed population (“XX yeasts in YY fields”); consequently
a “treat what you see” trial therapy approach with topical or
systemic antifungal drugs is routinely required to establish the
clinical significance of an observed population. A recent clinical
consensus guideline document presents a detailed diagnostic
algorithm for use in the veterinary clinic (Bond et al., 2020).
The importance for investigating and correcting concurrent
skin diseases and other predisposing factors, where possible,
cannot be over-emphasized, if a chronic or relapsing course is to
be prevented.
Cytology using swabs of lesions rolled onto glass slides
is normally best restricted to use in the ear canal, as the
yield of squames and yeast from the skin is inferior to that
obtained by tape strips and dry scrapes (Bond and Sant, 1993;
White et al., 1998; Bensignor and Carlotti, 1999). In a recent
randomized, blinded prospective study of 30 dogs with otitis
externa, cytological specimens obtained using a conventional
cotton-tipped swab contained comparable numbers of yeasts
and bacteria, but fewer inflammatory cells, when compared with
samples prepared by aspiration of material from the horizontal
canal with a soft rubber feeding tube (Choi et al., 2018). In an
effort to improve upon the sensitivity of cytological sampling for
M. pachydermatis in the canine ear, Puig et al. have developed
a quantitative PCR method based on amplification of the single
copy ß-tubulin gene (Puig et al., 2019). The authors judged that
the results were accurate and showed improved sensitivity over
cytology; this method may have useful applications in diagnosis
and therapeutic monitoring, and in studies of pathogenesis and
therapeutic product development.
ANTIFUNGAL DRUG SUSCEPTIBILITY
TESTING FOR M. PACHYDERMATIS
Antimicrobial resistance has emerged globally as a serious
threat to human and animal health (Fera et al., 2009). Recent
publications (Brilhante et al., 2018; Schlemmer et al., 2019a)
support previous observations that most wild-type Malassezia
yeasts remain susceptible to the commonly-used azole drugs
such as itraconazole, ketoconazole and miconazole, although
efficacy of fluconazole is more variable (Velegraki et al., 2004;
Cafarchia et al., 2012a,b; Weiler et al., 2013). InM. pachydermatis
isolates from canine otitis externa, synergistic interactions have
been reported between between caspofungin and itraconazole or
fluconazole (Schlemmer et al., 2019a), whereas amphoterecin B
antagonized the activity of itraconazole, but not fluconazole or
posaconazole (Alvarez-Perez et al., 2019).
In view of routine susceptibility and an absence of standard
methods appropriate for theMalassezia genus, diagnostic testing
in veterinary practice tends to rely upon cytological rather
than cultural methods. However, laboratory studies of M.
pachydermatis have previously demonstrated that it is possible to
select for resistance to terbinafine and azoles (Nakano et al., 2005;
Jesus et al., 2011). Of greater concern are recent sporadic reports
of therapeutic failure with azoles in canine M. pachydermatis-
associated dermatitis that were associated with increased azole
tolerance in vitro; this might reflect the chronic and relapsing
course of Malassezia dermatitis and otitis that often necessitate
frequent and lengthy treatment courses (Chiavassa et al., 2014;
Watanabe et al., 2014).
Angileri et al. isolated M. pachydermatis from an azole-
unresponsive toy poodle that had MICs that were several
fold higher when compared with strains from untreated dogs
(Angileri et al., 2019). Kano et al. showed that an isolate of
M. pachydermatis with MICs of itraconazole and ketoconazole
of >32 mg/L by Etest had mis-sense mutations in the ERG11
gene that encodes lanosterol 14 –alpha-demethylase, the target
site for antifungal azoles (Kano et al., 2019b). Mutations in the
same gene were described in field isolates with tolerance to
ravuconazole (Kano et al., 2019a) and in miconazole-resistant
clones of CBS1879 (the neotype culture of M. pachydermatis)
selected by serial passage on miconazole supplemented media
(Kano and Kamata, 2019). Azole resistance in M. pachydermatis
has also been associated with quadruplication of the ERG11
gene (Kim et al., 2018). By contrast, mutations in drug efflux
pumps, a common mechanism of azole resistance in Candida
species (Sanguinetti et al., 2005), has not yet been reported in
the genusMalassezia. The emergence of azole resistance amongst
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Malassezia species warrants careful surveillance and product
stewardship to ensure ongoing utility of this important drug class.
Further data are urgently required to establish whether topical
therapies are preferable to systemic treatments in this context,
and to guide antimicrobial stewardship policies for antifungal
therapy in small animal practice.
Concern over azole resistance has prompted heightened
interest in alternative antifungal agents. There are reports of
in vitro efficacy against M. pachydermatis of a honey-based
gel (Oliveira et al., 2018), monensin and, to a lesser extent,
narasin (polyether ionophores originally marketed as anti-
coccidials and growth-promoting modifiers of the bovine rumen
flora; Chan et al., 2018, 2019). Multiple recent publications
have explored the potential antifungal utility of essential oils,
complexmixtures of highly concentrated aromatic oils (primarily
terpenes and/or phenylpropanoids) extracted from plants by
steam distillation, hydrodiffusion or pressure (Manion and
Widder, 2017; Bismark et al., 2019). A previous randomized
clinical trial reported persistent efficacy of a commercial essential
oil product (Malacalm, Flora Slr Oli essenziali, Lorenzana,
Italy) applied twice daily for 1 month to dogs with Malassezia
dermatitis (Nardoni et al., 2014), although the study is weakened
by incomplete data on randomization and clinical scores (Bond
et al., 2020). Publications between 2013 and 2018 were usefully
reviewed by Donato et al. (2019). Most of the recent studies
have been conducted in vitro and their utility in clinical practice
remains largely untested. Comparisons between studies are
hampered by an absence of agreed standard testing methods
that are not yet optimized, arbitrary assignment of interpretative
criteria, and likely batch variation in activities of essential oils
prepared by different methods (Bismark et al., 2019). Recently,
anti-Malassezia effects have been observed in vitro using winter
savory, lemon grass, oregano, palmarosa and cinnamon leaf oils
by agar disc diffusion and vapor assays (Bismark et al., 2019).
Oregano oil and thyme oil and their major phenolic components
(carvacrol, thymol) were fungicidal against M. pachydermatis
when tested using agar dilution (Sim et al., 2019). There are
recent reports of synergistic interactions between essential oil
components and azoles or nystatin against M. pachydermatis,
including carvacrol and miconazole or nystatin, thymol and
nystatin (Schlemmer et al., 2019b), and between clotrimazole
and essential oils of Melaleuca alternifolia, Mentha piperita, and
Origanum vulgare (Bohmova et al., 2019).
TREATMENT OF MALASSEZIA
DERMATITIS IN DOGS
A recent evidence-based review on the treatment of canine
Malassezia dermatitis reported “strong” evidence for the use
of a 2% miconazole and 2% chlorhexidine shampoo, used
twice weekly (Bond et al., 1995, 2020; Maynard et al., 2011).
“Moderate” evidence was available for a 3% chlorhexidine
shampoo (Maynard et al., 2011; Bond et al., 2020). For canine
cases where topical therapy is ineffective or impractical, there was
“moderate” evidence for the use of ketoconazole at 5–10 mg/kg
orally once or twice daily; and itraconazole at 5 mg/kg orally
once daily or two consecutive days per week (reviewed by Bond
et al., 2020). Recently, the clinical and cytological effects of a
once daily application of a leave-on spray formulation containing
zinc, ethyl lauroyl arginate, laureth-9, urea, panthenol, glycerine
and butylene glycol (Aptus R© Derma Spot On ConcentrateTM,
Orion Pharma Animal Health, Sollentuna, Sweden) were
evaluated in a randomized, blinded, controlled study of 18
dogs with chronic pododermatitis associated with Malassezia
yeasts (Sjostrom et al., 2018). When compared with placebo
treatment of the contralateral foot, reduced yeast counts from
the actively treated foot were associated with a reduction in
clinical scores.
In dogs, persistent or recurrent Malassezia dermatitis
are usually associated with failure to identify and correct
predisposing or perpetuating factors. However, the evidence that
reduced susceptibility of M. pachydermatis to commonly used
antifungal drugs may develop under both field and laboratory
conditions highlights the need for surveillance and vigilance for
the emergence of clinically-relevant resistance. Agreed reference
methods to assess antifungal susceptibility of M. pachydermatis
are required to assist veterinary practitioner for the management
of chronic cases.
POTENTIAL TRANSMISSION OF
MALASSEZIA YEASTS FROM ANIMALS TO
HUMANS
The zoonotic potential of Malassezia yeasts was first defined in
the context of a neonatal intensive care unit, where a cluster
of low birth weight patients receiving lipid emulsions were
colonized byM. pachydermatis that was likely introduced on the
hands of health care workers transmitted by contact with pet dogs
(Chang et al., 1998). Once introduced to a facility, Malassezia
yeasts can persist on incubator surfaces for prolonged periods
of time (Van Belkum et al., 1994). A subsequent case report
described a facial granuloma caused by M. pachydermatis in a
dog owner (Fan et al., 2006), and recently M. pachydermatis-
associated fungemia has been reported in a small number
of adults with various predisposing factors (Choudhury and
Marte, 2014; Roman et al., 2016; Lee et al., 2019). Since hand
contamination by M. pachydermatis is common amongst dog
owners, especially in owners of allergic dogs with Malassezia
overgrowth (Morris, 2005), there is a clear need for rigorous
hand hygiene by individuals in contact with pet dogs and cats,
especially when there is contact with immunocompromised
individuals (Bond et al., 2020).
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